{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:42:22Z","timestamp":1790401342125,"version":"4.1.0"},"reference-count":69,"publisher":"American Society for Clinical Investigation","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["P50CA097186,R50CA221836,R01CA266452,R50CA274336,P30CA015704"],"award-info":[{"award-number":["P50CA097186,R50CA221836,R01CA266452,R50CA274336,P30CA015704"]}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"crossref","award":["PC230582,PC230420,W81XWH-14-2-0183"],"award-info":[{"award-number":["PC230582,PC230420,W81XWH-14-2-0183"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"crossref","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017453","name":"Institute for Prostate Cancer Research","doi-asserted-by":"crossref","award":["Award"],"award-info":[{"award-number":["Award"]}],"id":[{"id":"10.13039\/100017453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:p>Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive subtype of prostate cancer (PC) without curative treatments. Antibody-drug conjugates (ADCs) emerged as promising cancer therapeutics that selectively deliver cytotoxic agents (payloads) to the tumors. Although ADCs have been successfully applied to treat hematological and solid tumors, ADC monotherapy has not demonstrated durable responses in mCRPC, and mechanisms of PC resistance to ADCs have not been thoroughly investigated. Our study aimed to improve ADC efficacy using an integrated approach for a custom ADC design and multiplexing. To nominate rational combinations of ADC targets and payloads, we (a) examined protein coexpression of 3 clinically relevant surface antigens \u2014 B7-H3, PSMA, and STEAP1 \u2014 in human mCRPCs and (b) screened established ADC payloads and their combinations in mCRPC cell lines with different molecular backgrounds. Identified synergistic interactions between DNA-damaging payloads and the BCL-XL inhibitor A-1331852 as well as their coordinated induction of the intrinsic apoptosis pathway were evaluated in PC cell lines. Functional relevance between isolated p53 loss and PC responses to 3 genotoxic ADCs \u2014 B7-H3\u2013seco-DUBA, PSMA-SG3249, and STEAP1-DXd \u2014 and their combinations with A-1331852 were established using genetic knockout models. Lastly, enhanced in vivo antitumor activity of vobramitamab duocarmazine by systemic A-1331852 was shown. Collectively, our findings provide rationale for development of ADC therapies combining genotoxic payloads with BCL-XL inhibitors for mCRPC.<\/jats:p>\n                  <jats:p>The study presents a framework for combinations of antibody-drug conjugate targets and payloads that may be applied to improve the treatment of late-stage prostate cancer.<\/jats:p>\n                  <jats:p\/>","DOI":"10.1172\/jci200438","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:10:15Z","timestamp":1782400215000},"source":"Crossref","is-referenced-by-count":1,"title":["Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer"],"prefix":"10.1172","volume":"136","author":[{"given":"Galina","family":"Semenova","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA."},{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-944X","authenticated-orcid":true,"given":"Sander B.","family":"Frank","sequence":"additional","affiliation":[{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-6551","authenticated-orcid":true,"given":"Ruth","family":"Dumpit","sequence":"additional","affiliation":[{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Han","sequence":"additional","affiliation":[{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilsa","family":"Coleman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-6567","authenticated-orcid":true,"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan D.","family":"Dirican","sequence":"additional","affiliation":[{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarana","family":"Arman","sequence":"additional","affiliation":[{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Maruwan","sequence":"additional","affiliation":[{"name":"Human Biology Division and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[{"name":"Human Biology Division and"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA."},{"name":"Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Human Biology Division and"},{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA."},{"name":"Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA."},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA."},{"name":"Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA."},{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-2180","authenticated-orcid":true,"given":"John K.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA."},{"name":"Human Biology Division and"},{"name":"Parker Center for Cancer Immunotherapy at UCLA, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0179"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.04.007"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34490"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030394"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01509-2"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.03.001"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0964"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37874-2"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162148"},{"issue":"supplement 2","key":"B13","article-title":"1842TiP phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)","volume":"34","author":"De Bono","year":"2023","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.004"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23765"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.222844"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(03)00190-4"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128212"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.003"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.089276"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00289-6"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.01.019"},{"issue":"21","key":"B29","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040774"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90613-P"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6371-0"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/ja00097a006"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/np300913h"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0037"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031270"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1845"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2941"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00062"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/jm060319f"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.8b00093"},{"issue":"1","key":"B43","first-page":"103","article-title":"Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel","volume":"33","author":"Jiang","year":"2008","journal-title":"Int J Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs140"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.2.1508"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401925"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00629-4"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0775"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nature11125"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05408-1"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60238-x"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00568"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4642"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2550"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402081"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.037"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802354115"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3396"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102764"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.232"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210048"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010051"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.016"},{"key":"B68","doi-asserted-by":"crossref","unstructured":"Pachitariu M, et al. Cellpose-SAM: superhuman generalization for cellular segmentation [preprint]. https:\/\/doi.org\/10.1101\/2025.04.28.651001 Posted on bioRxiv May 1, 2025","DOI":"10.1101\/2025.04.28.651001"},{"key":"B69","doi-asserted-by":"crossref","unstructured":"Frank S, et al. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies [preprint]. https:\/\/doi.org\/10.7554\/eLife.100081.1 Posted on eLife November 22, 2024","DOI":"10.7554\/eLife.100081.1"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/200438\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:50:38Z","timestamp":1785700238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/200438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":69,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1172\/JCI200438"],"URL":"https:\/\/doi.org\/10.1172\/jci200438","relation":{},"ISSN":["1558-8238"],"issn-type":[{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"e200438"}}